Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCCAM Stakeholders Call For Community-Based Research

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary and Alternative Medicine should focus additional attention on using community resources to fund research, according to a number of stakeholders

You may also be interested in...



NCCAM Should Stress Chronic Disease Prevention in “At Risk” Groups – CRN

A shift in focus of federally funded research on dietary supplements to include more study of chronic disease prevention in "at risk" populations would be more in line with market realities - in addition to providing a public health benefit, the Council for Responsible Nutrition says

NCCAM Should Stress Chronic Disease Prevention in “At Risk” Groups – CRN

A shift in focus of federally funded research on dietary supplements to include more study of chronic disease prevention in "at risk" populations would be more in line with market realities - in addition to providing a public health benefit, the Council for Responsible Nutrition says

NCCAM Should Stress Chronic Disease Prevention in “At Risk” Groups – CRN

A shift in focus of federally funded research on dietary supplements to include more study of chronic disease prevention in "at risk" populations would be more in line with market realities - in addition to providing a public health benefit, the Council for Responsible Nutrition says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel